Arcadia agrees to sell DailyMed to Walgreen
It looks like Arcadia Resources Inc.’s DailyMed pharmacy business will live on—but under the wing of Walgreen Co. instead of on its own.
Pharmaceutical
Articles
Lilly enters drug-development deal with Immunogen
Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.
Drugmaker eyes ex-Pfizer plant in western Indiana
Officials say an as-yet-unnamed drug company is looking to take over much of the former Pfizer Inc. complex near Terre Haute that had about 800 workers before it was shut down.
Endocyte shares plunge on clinical trial results
Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
Lilly shares rise on possibility for Alzheimer’s drug
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
Takeda, Lilly may face thousands of suits over Actos claims
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.
Drugmakers, pharmacists at odds
Indianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins, leading CVS to kick Lilly’s insulins off its list of recommended drugs.
Lilly committed to China despite IP woes
Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.
Potential Lilly drug doubles good cholesterol
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
Cash-strapped Arcadia seeks DailyMed buyer
The Indianapolis-based company is searching for a buyer for its once-promising DailyMed pharmacy service as it struggles to pay $30 million in debt that comes due in April.
Potential Effient rival shows promise in study
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
Lilly, Amylin agree to end diabetes partnership
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
Lilly, Bristol-Myers approved to market wider Erbitux use
Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.
Drug shortages hit Lilly, Endocyte
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
Lilly loses British Supreme Court ruling over gene patent
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
Lilly wins European approval for new use of Alimta
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
Zyprexa era comes to an end for Lilly
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
Lilly fights view that fate hinges on Alzheimer’s drug
Analysts have eyes on trial data for drug that could be a game-changer for the company.
FDA approves first generic versions of Zyprexa
Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.